Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
DHT Holdings, Inc. (DHT) - free report >>
CytomX Therapeutics, Inc. (CTMX) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DHT Holdings, Inc. (DHT) - free report >>
CytomX Therapeutics, Inc. (CTMX) - free report >>
Image: Bigstock
Top Ranked Momentum Stocks to Buy for April 3rd
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 3rd:
electroCore, Inc. (ECOR - Free Report) : This bioelectronic medicine company has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 48.7% over the last 60 days.
electroCore, Inc. Price and Consensus
electroCore, Inc. price-consensus-chart | electroCore, Inc. Quote
electroCore’s shares gained 5.1% over the last one month above the S&P 500’s decrease of 12.8%. The company possesses a Momentum Score of A.
electroCore, Inc. Price
electroCore, Inc. price | electroCore, Inc. Quote
CytomX Therapeutics, Inc. (CTMX - Free Report) : This oncology-focused biopharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25.2% over the last 60 days.
CytomX Therapeutics, Inc. Price and Consensus
CytomX Therapeutics, Inc. price-consensus-chart | CytomX Therapeutics, Inc. Quote
CytomX Therapeutics’ shares gained 4.2% over the last one month. The company possesses a Momentum Score of A.
CytomX Therapeutics, Inc. Price
CytomX Therapeutics, Inc. price | CytomX Therapeutics, Inc. Quote
DHT Holdings, Inc. (DHT - Free Report) : This crude oil tankers operator has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 41.6% over the last 60 days.
DHT Holdings, Inc. Price and Consensus
DHT Holdings, Inc. price-consensus-chart | DHT Holdings, Inc. Quote
DHT’s shares gained 35% over the last one month. The company possesses a Momentum Score of A.
DHT Holdings, Inc. Price
DHT Holdings, Inc. price | DHT Holdings, Inc. Quote
Aytu BioScience, Inc. (AYTU - Free Report) : This specialty pharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.8% over the last 60 days.
Aytu Bioscience, Inc. Price and Consensus
Aytu Bioscience, Inc. price-consensus-chart | Aytu Bioscience, Inc. Quote
Aytu BioScience’s shares gained more than 100% over the last one month. The company possesses a Momentum Score of A.
Aytu Bioscience, Inc. Price
Aytu Bioscience, Inc. price | Aytu Bioscience, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>